丁苯酞对缺血性脑卒中患者的疗效及对血清中sTRAIL、HMGB1和IL-23的影响

The observation and expressions of sTRAIL, HMGB1 and IL-23 by Butylphthalide injection in patients with ischemic stroke

目的探讨丁苯酞治疗缺血性脑卒中的临床疗效,关注治疗对血清中可溶性相关凋亡诱导配体(sTRAIL)、高迁移率族蛋白B(HMGB1)和白细胞介素-23(IL-23)的影响。方法对本院收治的178例缺血性脑卒中患者进行观察,按入院顺序分为两组,对照组89例,应用常规治疗;观察组89例,在常规基础上加用丁苯酞治疗,同时抽取患者治疗前后的空腹静脉血,应用ELISA法检测两组患者治疗前后血清中sTRAIL、HMGB1和IL-23的影响。结果治疗3周后,观察组患者的总有效率明显高于对照组,两组患者治疗后血清中sTRAIL、HMGB1和IL-23的表达均下降,但观察组下降值明显高于对照组。结论丁苯酞对缺血性脑卒中患者的疗效明显,且能有效下调血清中sTRAIL、HMGB1和IL-23的含量,减少由于炎性细胞因子增高引起的神经细胞损伤。

Objective To observe the curative effect, sTRAIL, HMGB1 and IL-23 change by Butylphthalide injection in patients with ischemic stroke, for accumulating clinical experience, directing clinical treatment. Method 178 patients with ischemic stroke were divided into two groups. The control group （89 cases） were treated by routine treatment, the observation group （89 cases） were treated by routine and Butylphthalide injection. We observed the efficacy and change of sTRAIL, HMGB1 and IL-23 by ELISA in two groups. Result The total effective rate was obviously higher in the observation group than in the control group after 3 weeks. The change value of sTRAIL, HMGB1 and IL-23 were obviously higher in the observation group after treatment. Conclusion The treatment of Butylphthalide injection can improve the curative effect, regulate the expressions of sTRAIL, HMGB1 and IL-23 in patients with ischemic stroke, is worthy be recommended in clinical treatment.